Pancreatic Cancer Early Detection Consortium (NCT04970056)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Individuals from the following groups who present for clinical evaluation and assessment of PDAC risk at any of the participating sites can be offered participation in the PRECEDE database: Cohort 1 Individuals without history of PDAC meeting any of the following criteria:
2. 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.
3. 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family
4. BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family
5. Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+
6. Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+
7. Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+ Cohort 2 Individuals without history of PDAC meeting any of the following criteria:
8. ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+
9. 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family
10. 1 first degree relative with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member Cohort 3 Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2) Cohort 4 Individuals without history of PDAC presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort. Cohort 5 Individuals without history of PDAC who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and/or buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort. Cohort 6a Individuals diagnosed with PDAC or pancreatic high-grade dysplasia after enrollment in PRECEDE meeting any of the following criteria:
11. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
12. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11 Cohort 6b Individuals with a personal history of PDAC or pancreatic high-grade dysplasia meeting any of the following criteria:

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (60 Sites)

• Mayo Clinic Arizona — Phoenix, Arizona
• Honor Health Research Institute — Scottsdale, Arizona
• Providence Health and Services — Burbank, California
• City of Hope — Duarte, California
• UC San Diego Moores Cancer Center — La Jolla, California
• Cedars-Sinai Medical Center — Los Angeles, California
• UCLA Health — Los Angeles, California
• Hoag — Newport Beach, California
• UC Irvine Health — Orange, California
• UC Davis — Sacramento, California
• University of California, San Francisco (UCSF) — San Francisco, California
• Yale University — New Haven, Connecticut
• Mayo Clinic Jacksonville — Jacksonville, Florida
• University of Miami — Miami, Florida
• Moffitt Cancer Center — Tampa, Florida
• Emory University Hospital — Atlanta, Georgia
• Illinois CancerCare — Bloomington, Illinois
• University of Chicago Medicine — Chicago, Illinois
• NorthShore University HealthSystem — Evanston, Illinois
• University of Kansas Medical Center — Kansas City, Kansas
• Massachusetts General Hospital — Boston, Massachusetts
• Umass Memorial Medical Center — Worcester, Massachusetts
• University of Michigan — Ann Arbor, Michigan
• Beaumont/Corewell Health — Royal Oak, Michigan
• University of Nebraska Medical Center — Omaha, Nebraska

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.